The Pro-inflammatory Cytokine TNF-a Regulates the Activity

and Expression of the Serotonin Transporter (SERT)

in Astrocytes by Malynn, Sandra et al.
ORIGINAL PAPER
The Pro-inflammatory Cytokine TNF-a Regulates the Activity
and Expression of the Serotonin Transporter (SERT)
in Astrocytes
Sandra Malynn • Antonio Campos-Torres •
Paul Moynagh • Jana Haase
Received: 6 September 2012 / Revised: 20 December 2012 / Accepted: 26 December 2012 / Published online: 22 January 2013
 Springer Science+Business Media New York 2013
Abstract Pro-inflammatory cytokines have been impli-
cated in the precipitation of depression and related disor-
ders, and the antidepressant sensitive serotonin transporter
(SERT) may be a major target for immune regulation in
these disorders. Here, we focus on astrocytes, a major class
of immune competent cells in the brain, to examine the
effects of pro-longed treatment with tumor necrosis factor-
alpha (TNF-a) on SERT activity. We first established that
high-affinity serotonin uptake into C6 glioma cells occurs
through a SERT-dependent mechanism. Functional SERT
expression is also confirmed for primary astrocytes. In both
cell types, exposure to TNF-a resulted in a dose- and time-
dependent increase in SERT-mediated 5-HT uptake, which
was sustained for at least 48 h post-stimulation. Further
analysis in primary astrocytes revealed that TNF-a
enhanced the transport capacity (Vmax) of SERT-specific
5-HT uptake, suggesting enhanced transporter expression,
consistent with our observation of an increase in SERT
mRNA levels. We confirmed that in both, primary astro-
cytes and C6 glioma cells, treatment with TNF-a activates
the p38 mitogen-activated protein kinase (MAPK) signal-
ing pathway. Pre-treatment with the p38 MAPK inhibitor
SB203580 attenuated the TNF-a mediated stimulation of
5-HT transport in both, C6 glioma and primary astrocytes.
In summary, we show that SERT gene expression and
activity in astrocytes is subject to regulation by TNF-a, an
effect that is at least in part dependent on p38 MAPK
activation.
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Introduction
High-affinity re-uptake of the neurotransmitter serotonin
(5-hydroxytryptamine, 5-HT) is mediated by the serotonin
transporter (SERT), exerting precise spatial and temporal
control over the physiological actions of this neurotrans-
mitter. Consistent with the importance of the physiological
processes governed by SERT, this protein is subjected to a
network of regulatory influences. The regulation of SERT
gene expression by numerous stimuli has been extensively
studied in particular in a number of model cell lines of both
central and peripheral origin, i.e. SERT gene expression
appears to be subject to regulation by a variety of stimuli,
including cAMP [1–5], BDNF [3], steroid hormones [6–8],
and growth factors [9, 10]. In addition, correlations have
been established between the expression and activity of
SERT and a number of psychiatric disorders such as
obsessive compulsive disorder (OCD), autism and major
depressive disorder (MDD) [11].
Under physiological conditions there is intimate and
reciprocal communication between the nervous, immune
and endocrine systems and alterations in this equilibrium
are known to be implicated in the onset of psychiatric ill-
ness, including major depression (for recent reviews see for
example Ref. [12, 13]). Elevated levels of pro-inflamma-
tory cytokines IL-1b, TNF-a and IL-6 has been reported in
patients suffering from neuropsychiatric disorders [12, 14–
16]. In addition, immune activation in human disease as
S. Malynn  A. Campos-Torres  J. Haase (&)
UCD School of Biomolecular and Biomedical Science, UCD
Conway Institute, University College Dublin, Dublin 4, Ireland
e-mail: jana.haase@ucd.ie
A. Campos-Torres  P. Moynagh
Institute of Immunology, National University of Ireland
Maynooth, Maynooth, Co., Kildare, Ireland
123
Neurochem Res (2013) 38:694–704
DOI 10.1007/s11064-012-0967-y
well as in animal models is often accompanied by a dis-
crete set of psychiatric and behavioral alterations which
bear many of the hallmarks of depressive illness [17, 18].
TNF-a is of particular interest as it is a pro-inflammatory
cytokine that has been shown to be intimately associated
with the development of MDD and is one of the few
cytokines where decreases in its serum concentration has
been shown to correlate with improvement of clinical
symptoms of the disease [19].
As the serotonin transporter has been intimately linked to
a variety of mood and behavioral disorders, not least as the
primary target for the most widely prescribed antidepressant
drugs, i.e. the selective serotonin reuptake inhibitors
(SSRI’s) such as fluoxetine, paroxetine and citalopram,
SERT represents a potential target for cytokine-induced
regulatory mechanisms contributing to the pathophysio-
logical processes underlying depressive illnesses. Indeed,
pro-inflammatory cytokines have been implicated in the
regulation of serotonergic homeostasis in vivo through the
modulation of central serotonin activity and metabolism [20,
21]. Studies assessing cytokine-mediated modulation of
SERT expression and/or activity have predominately been
conducted in SERT expressing cell lines of peripheral origin
[4, 22–26]. Comparatively little is known about the mecha-
nisms by which cytokines and other pro-inflammatory mol-
ecules may exert a functional influence on the transporter in
cells of the central nervous system i.e. neurons or glia. Zhu
et al. [27, 28] recently examined the acute regulation of
SERT by the pro-inflammatory cytokines TNF-a and IL-1b
in vitro and in vivo following peripheral immune challenge
by lipopolysaccharide. However, given the chronic nature of
depressive illness and related disorders as well as the fact that
chronic inflammatory disorders are characterized by pro-
longed elevation of pro-inflammatory molecules, cytokine-
dependent effects on mood and behavior potentially include
gene expression alterations, in addition to their acute effects
on SERT activity.
In the central nervous system, the serotonin transporter
has traditionally been perceived to be expressed predomi-
nantly in neuronal cells. As a consequence, the potential
physiological role of SERT expressed in non-neuronal cell
populations has been largely overlooked. However, in
recent years, several reports have been published providing
compelling evidence for the expression of functionally
active SERT in glial cells lines as well as in primary
astrocytes [10, 29–31]. High-affinity uptake of 5-HT by
astrocytes is sensitive to inhibition by antidepressants such
as imipramine and SSRIs, with a high degree of correlation
noted between the Ki values for inhibition of 5-HT uptake
by antidepressants in astrocytes and neurons, thus sug-
gesting that the pharmacologically indistinguishable, high-
affinity 5-HT uptake is mediated by SERT in both, glial
and neuronal cells [30, 32, 33]. Furthermore, in recent
years glial-derived SERT has been successfully visualized
in rat brain tissue [34, 35].
In this study, we provide evidence that glial cells may
contribute to the effects of the pro-inflammatory cytokine
on serotonin homeostasis. Following an initial thorough
characterization of SERT-mediated high-affinity 5-HT
uptake in C6 glioma cells and primary astrocytes, we show
that pro-longed treatment with pro-inflammatory cytokine
TNF-a substantially enhances SERT gene expression and
activity in these cells.
Materials and Methods
Reagents
TNF-a was purchased from R&D systems, Europe (Oxon,
UK). SB203580 was obtained from Calbiochem (Darms-
tadt, Germany). Anti-total and anti-phospho specific anti-
bodies for signaling intermediates were purchased from
Cell Signaling Technology (La Jolla, CA). [3H]5-HT
(5-hydroxytryptamine creatine sulphate, 28.1 Ci/mmol)
was obtained from Perkin Elmer Life Sciences (Boston,
MA). All chemicals unless otherwise stated were obtained
from Sigma (Ayrshire, UK).
Cell Culture and Primary Astrocyte Preparation
C6 glioma cells were maintained at 37 C in a humidified
atmosphere of 5 % CO2-95 % air in DMEM containing
10 % FBS, 2 mM L-glutamine, 100 units/ml penicillin and
100 lg/ml streptomycin. Primary astrocytes were prepared
as follows. P0 Wistar rats were humanely killed by cervical
dislocation, the cerebral cortices removed and separated
from the meninges. The cortical tissue was dissociated by
mechanical digestion and the cell suspension centrifuged at
1,000g for 5 min. Cell pellets were resuspended and cul-
tured in pre-equilibrated flasks in DMEM containing 10 %
FBS, 2 mM L-glutamine, 100 units/ml penicillin and
100 lg/ml streptomycin. Cells were cultured for 10 days at
37 C in a humidified 5 % CO2-95 % air atmosphere. Five
to 7 days prior to experiments cells were trypsinised and
re-plated onto 6 and 24 well dishes. The cellular compo-
sition of the astrocytic cultures was evaluated by immu-
nofluoresence studies with the astrocytic marker glial
fibrillary acidic protein (GFAP). Immunocytochemistry
showed that approximately 95 % of the cells in these cul-
tures stained positively for GFAP.
5-HT Transport Assay
[3H]5-HT transport activity was assayed through minor
modification of a technique described previously [36].
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Briefly, C6 glioma cells were plated 48 h, while the pri-
mary astrocytes were seeded down 5–7 days prior to
commencing the 5-HT transport assay. At the time of
assay, the medium was removed by aspiration and cells
washed with transport buffer (TB) containing 10 mM
HEPES, pH 7.5, 150 mM NaCl, 2 mM KCl, 1 mM CaCl2,
1 mM MgCl2, 1.8 g/l glucose, 100 lM pargyline and
100 lM ascorbic acid. The TB was removed and cells were
incubated in triplicate in TB at 37 C for a further 10 min.
In order to eliminate any non-specific, low affinity uptake
of [3H]5-HT by the norepinephrine transporter (NET), the
NET-specific inhibitor nisoxetine (100 nM final concen-
tration) was included in the TB. The 5-HT transport assay
was initiated by the addition of [3H]5-HT (100 nM) and
terminated 10 min later by the aspiration of the reaction
buffer followed by three rapid washes in ice-cold TB
containing 1 lM paroxetine. Cells were then solubilized in
2 % SDS and [3H]5-HT accumulation was evaluated by
scintillation counting. Specific 5-HT uptake was calculated
by determining the amount of [3H]5-HT accumulated in the
presence or absence of 1 lM escitalopram or paroxetine.
Saturation kinetics analysis of 5-HT transport was carried
out using increasing concentrations of 5-HT ranging from 0
to 4 lM. IC50 values for inhibition of 5-HT uptake by
various uptake inhibitors were carried out by adding
solutions of [3H]5-HT (final concentration 50nM) con-
taining a suitable concentrations range for each the
respective uptake inhibitor. To evaluate the effect of p38
MAPK inhibition by SB203580 (SB) on SERT activity,
primary astrocytes and C6 glioma cells were treated with
the specific p38 MAPK inhibitor SB203580 (10 lM) or
vehicle alone (DMSO, 1 % v/v final concentration) for
20 min followed by incubation for an additional 12 h in the
presence or absence of TNF-a (100 ng/ml) or with TNF-a
alone. Cells were then subjected to 5-HT transport assay
under conditions described above. Data analysis was car-
ried out using the SigmaPlot 8.0 software and kinetic
parameters were determined by non-linear regression
analysis.
Analysis of Signaling Kinase Activation
To monitor the activation of a number of previously
characterized signaling pathways in response to TNF-a
treatment, primary astrocytes and C6 glioma cells were
cultured in 6 well plates and treated for the indicated times
with TNF-a (100 ng/ml). Cells were lysed with RIPA
buffer (PBS containing 0.1 % SDS, 1 % Triton X-100,
0.1 % NP-40, 1X protease inhibitors (Roche), 50 mM
sodium orthovanadate, 50 mM sodium fluoride, 10 mM
beta-glycerophosphate) followed by centrifugation at
13,000 g for 20 min at 4 C, supernatants were mixed with
5 9 Laemmli buffer (0.3 M Tris, pH 6.8, 10 % (w/v) SDS,
0.1 % (w/v) bromophenol blue, 50 % (v/v) glycerol and
100 mM DL-dithiothreitol) and analysed by Western
blotting. Samples were subjected to SDS-PAGE followed
by transfer onto nitrocellulose membrane (Whatman).
Blotted membranes were subsequently blocked in 5 % (w/v)
non-fat dry milk or 3 % (w/v) BSA in TBST (137 mM
NaCl, 20 mM Tris pH 8.3, 0.5 % (v/v) Tween-20). Blots
were then incubated with anti-total and anti-phospho spe-
cific antibodies (1:1,000, Cell Signaling Technology) in
either 3 % (w/v) BSA or 5 % (w/v) non-fat dry milk
overnight at 4 C followed by incubation with either HRP-
conjugated anti-rabbit or anti-mouse secondary antibodies
(1:5,000, Cell Signaling Technology). Immunoreactive
bands were visualized following incubation of immuno-
blots with ECL solution (Pierce).
RNA Isolation and Quantitative Real-Time PCR
Total RNA was isolated from cells using TRI Reagent
(Sigma) following manufacturer’s instructions. RNA was
quantitated using the Nanodrop ND-1000 spectrophotom-
eter system (Labtech). Double stranded cDNA was syn-
thesized from total RNA (2 lg) following DNAse I
treatment using oligo dT primers and M-MLV Reverse
Transcriptase (Promega). The expression of the SERT gene
was examined using quantitative real-time reverse tran-
scription PCR using gene specific primers (Forward 50
GGCCTGGAAGGTGTGATCA 30 and Reverse 50GCGCT
TGGCCCAGATGT 30) and SYBR Green detection
chemistry. The real-time PCR reaction was carried out in a
Prism 7700HT Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA). Each reaction was per-
formed in duplicate and the fluorescent data was converted
into cycle threshold (CT) measurements and the DDCT
method was used to calculate fold expression changes. A
b-actin control primer and probe set (Applied Biosystems)
was used for normalization purposes.
Statistical Analysis
Experimental data was analyzed by Student’s t test for
single comparisons. In each case, the differences between
means were considered significant at p values of less than
0.05. For all transport experiments data represented are the
mean percentage of control values ± SEM obtained from 3
independent experiments as indicated in the figure legends.
Total uptake data was corrected for non-specific uptake and
analyzed by fitting to a Michaelis–Menten kinetics using
SigmaPlot version 8.0. Data represented in Figs. 4e, f were
subjected to a one-way ANOVA using a Newman-keuls
multiple comparison test.
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Results
High-Affinity 5-HT Uptake in C6 Glioma Cells is
Mediated by SERT
SERT-specific 5-HT uptake has been detected in primary
astrocytes and various glial cells lines [10, 29, 30], but to
our knowledge has not been reported for C6 glioma cells.
Thus, we utilized saturation kinetics and various mono-
amine transporter inhibitors to characterize the high-affin-
ity 5-HT uptake components in these cells. Serotonin
uptake was carried out as described in Materials and
Methods; preliminary experiments showed that 5-HT
uptake in these cells was linear for up to 20 min (data not
shown). Uptake specificity was determined in the presence
of the highly specific SERT inhibitor escitalopram. The
kinetic parameters obtained were: Vmax = 368 ± 19 fmol/
min/106 cells, Km = 510 ± 76 nM (Fig. 1a), indicating
high-affinity serotonin uptake in these cells. Furthermore,
using 100 nM 5-HT pre-treatment with the NET inhibitor
nisoxetine resulted in only a marginal reduction of 5-HT
uptake to 91 ± 8 % of control, suggesting that at low
serotonin concentration non-specific uptake of 5-HT by
NET accounted for no more than approximately 10 % of
total uptake in C6 glioma cells. In contrast, citalopram and
paroxetine, highly selective SERT inhibitors almost com-
pletely abolished 5-HT uptake in these cells at an inhibitor
concentration (100 nM), which effectively blocks SERT,
but does not significantly affect any other monoamine
uptake systems (Fig. 1b). Using 50nM [3H]5-HT, we
obtained average IC50 values for three well characterized
SERT inhibitors: paroxetine, 0.66 ± 0.14 nM; escitalop-
ram, 1.2 ± 0.35 nM; imipramine, 35.4 ± 1.6 nM. These
values as well as the order of potency of these inhibitors,
i.e. paroxetine [ escitalopram [ imipramine, is highly
consistent with previously reported findings for SERT-
mediated 5-HT uptake [37, 38]. Thus, we conclude that
high-affinity 5-HT uptake into C6 glioma cells is largely
SERT-dependent. Although, NET-mediated uptake of
5-HT accounts for only a minor portion of the 5-HT uptake
C6 glioma cells, NET-mediated 5-HT uptake was inhibited
in all subsequent 5-HT transport assays by adding nisox-
etine to the uptake buffer at 100 nM, a concentration that
does not significantly affect SERT-specific 5-HT uptake.
Fig. 1 C6 glioma cells exhibit high-affinity, SERT-mediated 5-HT
uptake. a Saturation kinetics of 5-HT uptake into C6 cells was carried
out as described in ‘‘Materials and Methods’’. Kinetic parameters
were determined by non-linear regressing analysis using the Michae-
lis-Menton equation, values are: Vmax = 368 ± 19 fmol/min/10
6
cells, Km = 510 ± 76 nM. The graph shown is representative of
three independent experiments, each giving similar results. b Pharma-
cological characterization of 5-HT uptake. 5-HT uptake was carried
out in the absence and presence of monoamine transport inhibitors
nisoxetine (Nisox, 100 nM, specific inhibitor of norepinephrine
tranporter), paroxetine (Parox, 100 nM, SERT-selective) and citalo-
pram (Citalo, 100 nM, highly SERT-specific). Values are expressed
as the mean percentage of control ± SEM of triplicate values and are
representative of 3–5 independent experiments. Asterix indicate a
statistically significant change in 5-HT uptake as compared to control,
*p \ 0.05, ***p \ 0.001 (Student’s t test). c IC50 values for
inhibition of 5-HT uptake were determined as described in ‘‘Materials
and Methods’’. Background was defined as uptake in presence of
1 lM paroxetine and subtracted from raw data. The graph shown is a
representative of 2–3 independent experiments. Mean IC50 values
obtained were paroxetine, 0.66 ± 0.14 nM; escitalopram, 1.2 ±
0.35 nM; imipramine, 35.4 ± 1.6 nM
c
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TNF-a Stimulates SERT Activity in C6 Glioma Cells
Having established SERT-specific 5-HT uptake in C6 cells,
we used this cell culture model to investigate the regulatory
effects of pro-inflammatory cytokines in isolated glial cells,
focusing in this study on TNF-a. As shown in Fig. 2a, b,
TNF-a treatment results in a dose- and time-dependent
increase in SERT-mediated 5-HT uptake in C6 glioma cells.
TNF-a mediated stimulation of 5-HT transport in C6 glioma
reached statistical significance upon treatment with 10 ng/
ml of TNF-a, however, this increased further upon treatment
with up to 100 ng/ml TNF-a (144.5 ± 10.1 % of control,
Fig. 2a). Using 100 ng/ml TNF-a stimulation of 5-HT
transport was found to reach statistical significance at 24 h
post-stimulation and was sustained thereafter with a further
increase in SERT-mediated 5-HT uptake at 48 h post-stim-
ulation (144.3 ± 4.8 % compared to control, Fig. 2b).
TNF-a Stimulates SERT Gene Expression and Activity
in Primary Astrocytes
In order to rule out that the TNF-a mediated stimulation of
SERT activity was confined to C6 glioma cells and thus,
potentially an artifact of the immortalization of this cell line,
we investigated whether this effect could also be observed in
primary astrocytes. In primary astrocytes, nisoxetine-sensi-
tive NET mediated non-specific uptake of 5-HT accounted
for no more than 20 % of total uptake of 5-HT (82 ± 2 % of
control). SSRI antidepressants paroxetine and citalopram
reduced 5-HT uptake to 34 ± 1.8 and 42 ± 2.6 % of con-
trol, respectively (Fig. 3a). Thus, under the conditions used
here approximately 60 % of total 5-HT uptake into primary
astrocytes is SERT-mediated. The remaining approximately
20 % 5-HT uptake may be mediated by low-affinity uptake
systems, such as the extraneuronal monoamine transporter,
also known as the organic cation transporter 3, which was
found to be expressed in human astrocytes [39].
As in C6 glioma cells, treatment with TNF-a enhances
SERT-specific 5-HT uptake in these cells in a concentra-
tion and time-dependent manner. A significant increase of
5-HT uptake was observed at 10 ng/ml TNF-a, saturation
was reached at approximately 25 ng/ml, with only a small
additional increase seen at 100 ng/ml, resulting in a max-
imal enhancement of SERT-mediated 5-HT uptake to
178.2 ± 18.0 % of control values (Fig. 3b). Furthermore,
TNF-a treatment (100 ng/ml) resulted in a significant
stimulation of SERT activity in these cells at 24 h, while
the most pronounced increase was observed at 48 h
(258.0 ± 19.1 % compared to control, Fig. 3c). We noted
that even at 12 h TNF-a induced an increase in SERT
activity, although this was not found to be statistically
significant, most likely due to a high degree of variability
of basal SERT activity in control cells. However, as shown
below (Fig. 4), strict control of experimental conditions,
such as the number of days in vitro (DIV) and the use of the
same batch of serum in the cell culture medium, results in a
reduced variability in basal SERT activity levels and
consequently a clear, statistically significant difference
between control and TNF-a treated cells at 12 h. Similar
effects of TNF-a were observed in both, C6 cells and
primary astrocytes, however, it is notable that primary
astrocytes are more sensitive to TNFa, i.e. the magnitude
of the increase in 5HT uptake activity was substantially
greater when compared to C6 glioma cells (258 vs. 144 %
of control, 100 ng/ml TNF-a, 48 h).
Kinetic analysis of SERT activity in primary astrocytes
revealed thatTNF-a treatment resultedinasignificant increase
in the maximal transport capacity Vmax (83.3 ± 4.0 vs.
153.4 ± 7.8 fmol/min/well) without significant alteration of
the Km value (203.0 ± 37.6 vs. 149.5 ± 29.3 nM) (Fig. 3d).
Fig. 2 TNF-a treatment results in a time and dose-dependent
increase in SERT activity in C6 glioma cells. a Dose dependence:
C6 glioma cells were treated with the indicated concentrations of
TNF-a for 24 h prior to 5-HT transport assay. b Time course: C6
glioma cells were treated with TNF-a (100 ng/ml) for the times
indicated and alteration in SERT activity was monitored by 5-HT
transport assay. Values in a and b are expressed as the mean
percentage of control ± SEM of triplicate values from three
independent experiments. Asterix indicate a statistically significant
change in 5-HT uptake as compared to control, **p \ 0.01 (Student’s
t test)
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Since the predominant effect on the Vmax value for 5-HT
uptake could be the result of enhances SERT expression, we
monitored SERT gene expression in these cells by quantitative
real-time PCR upon treatment with TNF-a (100 ng/ml). As
seen in Fig. 3e, TNF-a treatment resulted in a significant,
approximately4.5 fold increase inSERTmRNAasearlyas6 h
post stimulation, with a sustained increase in SERT gene
expressionobservedat12and 24 h.Thus, the TNF-amediated
stimulationofSERTactivity inprimaryastrocytes is likelydue
to an increase in SERT gene expression.
Fig. 3 TNF-a treatment results in a time and dose-dependent
stimulation of SERT gene expression and activity in primary
astrocytes. a Pharmacological characterization of 5-HT uptake in
primary astrocytes. 5-HT uptake was carried out in the absence and
presence of monoamine transport inhibitors nisoxetine (Nisox,
100 nM), paroxetine (Parox, 100 nM) and citalopram (Citalo,
100 nM). Values are expressed as the mean percentage of con-
trol ± SEM of triplicate values and are representative of three
independent experiments. Asterix indicate a statistically significant
change in 5-HT uptake as compared to control, *p \ 0.05,
**p \ 0.01, ***p \ 0.001 (Student’s t test). b Dose dependence
and c time course of TNF-a treatment: Primary astrocytes were
treated with the indicated concentrations of TNF-a for 24 h (b) or
with 100 ng/ml TNF-a for the indicated times (c) prior to 5-HT
transport assay. Values in b and c are expressed as the mean
percentage of control ± SEM of triplicate values from three
independent experiments. Asterix indicate a statistically significant
change in 5-HT uptake as compared to control, *p \ 0.05,
**p \ 0.01 (Student’s t test). d Analysis of transport kinetics upon
TNF-a mediated stimulation of SERT activity in primary astrocytes.
Cells were treated with TNF-a (100 ng/ml) for 24 h prior to transport
assay carried out with increasing concentrations of 5-HT as indicated.
The graph shown is representative of three independent experiments;
values were determined in triplicate and plotted as mean ± SEM.
e Quantitative analysis of alterations in SERT gene expression
following treatment of primary astrocytes with TNF-a. Cells were
treated with TNF-a (100 ng/ml) for the indicated times and SERT
mRNA levels were monitored by quantitative real-time PCR. Values
are expressed as the mean fold induction ± SEM from three
independent experiments, *p \ 0.05 (Student’s t test)
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p38 MAPK Activation is Involved in the TNF-a
Mediated Stimulation of SERT Activity in C6 Glioma
Cells and Primary Astrocytes
Upon engagement of its cell surface receptors, TNF-a is
known to stimulate a number of signaling cascades [40].
We focused our attention on MAP kinase pathways. As
seen in Fig. 4a, b, p38 MAPK was transiently activated in
response to TNF-a treatment in both, C6 glioma cells and
primary astrocytes, as evaluated by an increase in the
phospho-p38 MAPK signal. In both cell types, phospho-
p38 immunoreactivity peaked at 5 min post-stimulation
and decreased thereafter, consistent with previous obser-
vations in these cells types [40, 41].
We next sought to link the transient activation of p38
MAPK to the subsequential TNF-a mediated stimulation of
SERT activity. Firstly, as seen in Fig. 4c, d, the activation
of p38 MAPK in response to TNF-a treatment is effec-
tively blocked by pre-treatment with SB203580 in C6
glioma cells (Fig. 4c) and primary astrocytes (Fig. 4d)
respectively, as evaluated by Western blotting using total
and phospho-specific p38 MAPK antibodies. C6 glioma
cells and primary astrocytes were then stimulated with
TNF-a in the presence or absence of SB203580 and sub-
sequent alteration in SERT activity was monitored by 5-HT
transport assay 12 h later. We chose the 12 h time point for
this series of experiments, as incubation times with TNF-a
in the presence of the SB203580 vehicle DMSO of 24 h or
Fig. 4 Effect of the inhibition of p38 MAPK by SB203580 on the
TNF-a mediated stimulation of SERT activity in primary astrocytes
and C6 glioma cells. a, b TNF-a treatment activates the p38 MAPK
pathway in C6 glioma cells (a) and primary astrocytes (b). Cells were
treated for the indicated times with TNF-a (100 ng/ml), cell lysates
were prepared and subjected to Western blotting, n = 2–3. c, d TNF-
a triggers p38 MAPK phosphorylation in C6 glioma (c) and primary
astrocytes (d) in an SB203580 (SB) sensitive manner. Cells were pre-
treated with SB203580 (10 lM) or vehicle (DMSO) for 20 min prior
to treatment with TNF-a (100 ng/ml) for 5 min. The ability of
SB203580 to inhibit the activation of p38 MAPK was evaluated by
Western blot analysis of cell lysates using a phospho-specific p38
antibody, n = 2. e, f Effect of p38 MAPK inhibition on the TNF-a-
mediated stimulation of SERT activity in C6 glioma cells (e) and
primary astrocytes (f). Cells were pre-treated with SB203580 (10 lM)
for 20 min followed by stimulation with TNF-a (100 ng/ml) for 12 h.
Alteration in SERT activity was evaluated by 5-HT transport assay.
Values in e and f are expressed as the mean percentage of
control ± SEM of triplicate values from three independent experi-
ments. Changes in 5-HT uptake were compared to the corresponding
control value, i.e. TNF-a versus control, TNF-a versus TNF-a ? SB;
***p \ 0.001, **p \ 0.01 or *p \ 0.05 (one-way ANOVA using the
Newman-Keuls multiple comparison test)
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more resulted in a reduction in cell viability (data not
shown). Exposure to SB203580 alone did not affect basal
5-HT uptake in C6 glioma cells (95.4 ± 7.2 % of control),
but upon pre-treatment with SB203580 the TNF-a medi-
ated increase in 5-HT uptake was reduced (122.5 ± 5.6 %
of control), compared to TNF-a treatment alone
(140.1 ± 12.2 % of control, Fig. 4e). Similarly, in primary
astrocytes SB203580 alone did not significantly affect
basal 5-HT uptake (95.4 ± 7.2 % of control), but attenu-
ated the TNF-a mediated stimulation of SERT activity
(191.0 ± 4.1 % of control), compared to TNF-a treatment
alone (228.5 ± 11.0 % of control, Fig. 4f). Thus, in both,
C6 glioma cells and primary astrocytes, the TNF-a medi-
ated stimulation of 5-HT uptake was partially blocked by
inhibition of p38 MAPK. These results implicate the p38
MAPK pathway in the TNF-a mediated stimulation of
SERT activity in astrocytes. However, our observation that
TNF-a-induced stimulation of 5-HT uptake is only par-
tially inhibited by the p38 inhibitor indicates that (an)
additional signaling pathway(s) may work in conjunction
with or by a mechanism distinct from p38 MAPK.
Discussion
In this study, we uncovered a functional link between the
pro-inflammatory cytokine TNF-a and the regulation of
serotonin transporter activity in glial cells. Although
research so-far has primarily focused on neuronal SERT, it
has been recognized that SERT is also expressed in glial
cells, as outlined in detail in the Introduction. Thus, it
seems plausible that glial SERT contributes significantly to
the maintenance of serotonergic homeostasis and neuro-
transmission. Indeed, with their sensitivity to inflammatory
signals and their close proximity to the synapse, astrocytes
are ideally equipped to elicit such influences.
In this study, we utilized two cell culture models to
isolate the glia-specific effect of pro-inflammatory cyto-
kines, specifically TNF-a, on SERT expression. For one of
our model systems, namely for primary astrocytes, evi-
dence for functional SERT expression already exists, and
we confirmed here results from earlier studies [30, 31, 33].
Although, the murine SERT promoter was found to be
active in C6 glioma cells [42], to our knowledge, SERT-
specific uptake had not previously been shown for our
second model. However, kinetic and pharmacological
parameters determined for high-affinity 5-HT uptake into
C6 cells in this study, are highly consistent with values
obtained for SERT-mediated serotonin uptake in other cells
and tissues [37, 38].
Treatment of C6 glioma cells and primary astrocytes
with TNF-a induced a significant and sustained increase in
SERT-mediated 5-HT uptake in both cell types. As we
show in primary astrocytes, the increase in SERT activity
was due to an increase in the transport capacity (Vmax)
without a significant alteration of the apparent affinity of
SERT for its substrate 5-HT (Km). Together with our
observation of increased SERT mRNA levels this suggests
that the increase in the Vmax of SERT-mediated 5-HT
uptake is due to enhanced expression of the SERT gene.
The upregulation of SERT gene expression in response
to TNF-a is in accordance with previous reports examining
the consequences of long term exposure of SERT
expressing human JAR choriocarcinoma cells to pro-
inflammatory cytokines. In JAR cells, exposure to IL-1b
for up to 16 h has been shown to mediate changes in SERT
activity, namely a dose-dependent increase in SERT
mRNA, an increase in SERT cell surface density and
consequently an imipramine sensitive increase in [3H]5-HT
uptake [24]. Studies conducted in the same cell line fol-
lowing treatment for up to 72 h with the pro-inflammatory
cytokines TNF-a and IL-6 revealed that TNF-a but not
IL-6 treatment resulted in an increase in the Vmax for 5-HT
transport in these cells [25]. Others have found a down-
regulation of SERT by TNF-a in enterocyte-like Caco-2
cells [43], suggesting cell-type specific effects of TNF-a.
We also observed that in primary astrocytes, TNF-a
treatment induced a far greater increase in SERT-mediated
5-HT uptake (approximately 250 % of control) than in C6
glioma cells (approximately 145 % of control). There are a
number of possible explanations for this discrepancy. C6
glioma cells are astrocytoma in nature, and the immortal-
ization and maintenance of this cell line in culture may
result in the modulation of normal signaling pathways, thus
possibly blunting the stimulatory effect of TNF-a on SERT
gene expression. C6 glioma cells may express a different
profile of TNF-a receptors than primary astrocytes. For
example, it has been shown that C6 glioma cells in the
unstimulated state preferentially express TNF-R1, how-
ever, upon stimulation with TNF-a there is upregulation of
the expression of TNF-R2. The balance between the dif-
ferential expression of these receptors may result in altered
responses to TNF-a [44]. Nonetheless, very similar time
courses and concentration profiles for SERT activation
were observed in both C6 glioma cells and primary astro-
cytes in this study.
As expected, upon treatment with TNF-a, the p38
MAPK signaling pathway becomes activated in these cells.
This pathway has previously been implicated in the acute
regulation of SERT activity in vitro [27, 45, 46] and in vivo
[28, 47, 48]. Our data presented here suggest that p38
MAPK is also involved in the chronic regulation of SERT
activity upon pro-longed cytokine exposure. The inhibition
of p38 MAPK activation resulted in a partial attenuation of
the TNF-a induced stimulation of SERT-mediated 5-HT
uptake in astrocytes. Thus, it seems that p38 MAPK
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activation is at least in part responsible for the TNF-a
induced increase in SERT activity in astrocytes. These
results also indicate that one or more additional mecha-
nisms exist by which TNF-a enhances the activity of
SERT.
There are a number of reasons to consider a potential
role for NF-jB-dependent pathways in the regulation of
SERT activity. Firstly, the SERT gene promoter is known
to contain a consensus NF-jB binding site, suggesting that
this transcription factor may be involved in the regulation
of SERT gene expression in response to inflammatory
stimulation [49]. Also, this transcription factor has previ-
ously been implicated in the precipitation of the clinical
manifestation of sickness behavior as blockade of NF-jB
activation following peripheral administration of IL-1b has
been shown to attenuate the depressive-like behavioral
effects of this peripherally administered cytokine in
experimental animals [50]. Finally, the stimulation of both,
primary astrocytes and C6 glioma cells, with TNF-a results
in the activation of the NF-jB signaling pathway [40, 51,
52]. Preliminary experiments in our laboratory confirmed
the activation of NF-jB upon TNFa treatment in C6 cells
and primary astrocytes (data not shown). Furthermore, we
sought to investigate the potential contribution of the NF-jB
signaling pathway to the TNF-a mediated stimulation of
SERT activity in primary astrocytes through the use of a
number of inhibitors of this pathway. However, we were
unable to clearly link NF-jB activation and SERT gene
expression and activity in these cells. At this point we do
not, however, exclude the possibility that the NF-jB sig-
naling pathway may contribute to the increase in SERT
gene expression and activity in response to TNF-a treat-
ment. A complex relationship relevant to SERT regulation
may exist in astrocytes between the NF-jB and other
pathways activated by TNF-a, consequently, the role of
NF-jB in the regulation of SERT gene expression remains
to be elucidated.
The magnitude of the TNF-a induced increase in SERT
mRNA levels and 5-HT uptake activity, observed in par-
ticular in primary astrocytes, indicates that these cells are
very sensitive to TNF-a mediated alteration in SERT gene
expression. This may in fact represent a molecular mech-
anism by which SERT expression is switched on under
pathophysiological conditions in glial cells, which nor-
mally express very little SERT in vivo [34]. We postulate
that under conditions of chronic inflammation, by
enhancing SERT mediated 5-HT uptake, the pro-longed
elevation of circulating pro-inflammatory cytokines such as
TNF-a could significantly impact on available extracellular
5-HT. Since astrocytes are known to rapidly degrade 5-HT
following uptake [53], enhanced astrocytic uptake would
significantly affect the turnover rate of this neurotrans-
mitter, resulting in a decrease in the total brain 5-HT
content. In summary, our findings support the hypothesis
that TNF-a may significantly influence central serotonergic
homeostasis through the modulation of glial localized
SERT activity, providing a possible link to molecular
pathways underlying depressive symptoms associated with
chronic inflammatory diseases.
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